Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics in Drug Discovery

Matthew Jarpe's Biography



Matthew Jarpe, Associate Vice President Of Biology, Acetylon Pharmaceuticals

Matthew Jarpe is an Associate Director of Biology at Acetylon Pharmaceuticals in Boston, Massachusetts. He received his PhD from Johns Hopkins and completed his postdoctoral training at National Jewish Medical Center. Prior to joining Acetylon he worked at Biogen and Surface Logix. At Acetylon he has helped develop highly selective inhibitors for HDAC6 as well as HDAC1 and 2. His work has focused on the non-oncology uses of HDAC inhibitors, primarily in neurologic indications.

Matthew Jarpe Image

HDAC6 Inhibition: Getting Microtubule Transport Back on Track

Wednesday, 27 January 2016 at 14:30

Add to Calendar ▼2016-01-27 14:30:002016-01-27 15:30:00Europe/LondonHDAC6 Inhibition: Getting Microtubule Transport Back on TrackEpigenetics in Drug Discovery in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

HDAC6 inhibition restores fast axonal transport along microtubules that is critical for neuronal health. Inhibition of HDAC6 is effective in animal models of peripheral neuropathy and neurodegenerative diseases.


Add to Calendar ▼2016-01-26 00:00:002016-01-27 00:00:00Europe/LondonEpigenetics in Drug DiscoveryEpigenetics in Drug Discovery in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com